Taysha Gene Therapies, Inc. (TSHA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.44B USD. 52-week range 3.69 to 7.30 USD. Data as of 2026-10-09.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 ...